Exelixis, Inc. $EXEL Shares Bought by Ieq Capital LLC

Ieq Capital LLC raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 86.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 713,624 shares of the biotechnology company’s stock after purchasing an additional 330,856 shares during the quarter. Ieq Capital LLC’s holdings in Exelixis were worth $31,278,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in Exelixis by 7.0% in the fourth quarter. Wells Fargo & Company MN now owns 674,441 shares of the biotechnology company’s stock valued at $29,561,000 after buying an additional 44,089 shares during the last quarter. Wealthspire Advisors LLC lifted its position in shares of Exelixis by 30.7% during the fourth quarter. Wealthspire Advisors LLC now owns 6,208 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 1,458 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Exelixis by 1.6% during the fourth quarter. Quadrant Capital Group LLC now owns 28,053 shares of the biotechnology company’s stock worth $1,230,000 after purchasing an additional 433 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Exelixis by 59.6% during the fourth quarter. Brooklyn Investment Group now owns 8,724 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 3,258 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Exelixis by 1.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,259,677 shares of the biotechnology company’s stock worth $186,705,000 after purchasing an additional 78,765 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 0.7%

Shares of NASDAQ:EXEL opened at $53.13 on Friday. The firm’s 50 day moving average price is $47.98 and its 200 day moving average price is $44.89. The stock has a market cap of $13.35 billion, a price-to-earnings ratio of 17.65, a price-to-earnings-growth ratio of 1.54 and a beta of 0.41. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $53.93.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 earnings per share. On average, equities analysts anticipate that Exelixis, Inc. will post 3.16 EPS for the current year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the sale, the executive vice president owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dana Aftab sold 43,451 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares in the company, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 219,170 shares of company stock valued at $10,620,641 over the last quarter. Insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EXEL. TD Cowen increased their price target on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley increased their price target on shares of Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Wells Fargo & Company increased their price target on shares of Exelixis from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Stifel Nicolaus increased their price target on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $47.35.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.